Because promethazine hydrochloride (C₁₇H₂₀N₂S·HCl, MW 320.88 g/mol) exhibits pronounced hygroscopicity at uncontrolled relative humidities above 60% RH, direct compression lines for veterinary tablet production require closed material transfer, desiccant-lined intermediate bulk containers, and pre-blend moisture verification by USP <921> Karl Fischer with a typical acceptance limit of ≤2.0% w/w. In one production-scale configuration, a 25 mg tablet blend is prepared by geometric dilution of promethazine hydrochloride into lactose monohydrate (60–75% w/w) and microcrystalline cellulose (20–35% w/w), followed by addition of croscarmellose sodium (2–4% w/w) and magnesium stearate (0.5–1.0% w/w). The mixture is blended in a bin blender at 12 rpm for 15 min after the lubricant is added; extended lubrication beyond 20 min on production-scale ribbon blenders has been observed to increase ejection force and reduce tablet hardness due to hydrophobic surface coverage. Compression on a 45-station rotary press with B-tooling is maintained between 8 kN and 16 kN; target hardness is 4–8 kp, and friability is kept below 1.0% per USP <1216>. Disintegration is assessed in 0.1 N HCl at 37±0.5 °C with a 15 min limit, while dissolution testing follows USP <711> Apparatus 2 at 50 rpm in 900 mL of 0.1 N HCl. Aqueous film coating with low-viscosity HPMC at 3–4% w/w solids is performed in a side-vented coating pan at 55–65 °C inlet air temperature and 8–10 °C dew point, with pan speed adjusted to maintain a tablet bed temperature of 38–42 °C. Long-term stability is evaluated in accordance with ICH Q1A(R2) at 25±2 °C / 60±5% RH and accelerated at 40±2 °C / 75±5% RH; photostability per ICH Q1B is mandatory because the phenothiazine chromophore undergoes rapid photo-oxidation to promethazine sulfoxide and related N-oxide species. Promethazine hydrochloride is incompatible with strong oxidizing agents; contact with peroxide residues from packaging film or starch carriers should be avoided.

Direct compression remains feasible only when promethazine hydrochloride content is below 35% w/w; above this level, the brittle fracture tendency of the phenothiazine salt and its high surface charge reduce tablet tensile strength and increase capping. For higher-strength tablets, dry granulation by roller compaction with a roll force of 6–12 kN/cm and screen mill speed of 70–100 rpm is used to densify the API-excipient blend before final compression. The granulation is compacted to a ribbon density of 1.1–1.3 g/cm³ and milled to a granule size of 200–800 μm. Dry granulation avoids the hydrolytic risk of wet massing but requires careful control of post-compaction temperature, as API surfaces can heat above 40 °C during roller compaction and accelerate sulfoxide formation. Packaging for finished tablets normally uses PVC/PVDC/aluminium blisters or induction-sealed HDPE bottles with silica gel desiccant; moisture ingress beyond 0.5 g/m²/day for barrier films has been associated with surface spotting and dissolution drift in tropical storage conditions.

What Limits Terminal Sterilization of Promethazine HCl Injection Solutions?

Terminal steam sterilization of promethazine hydrochloride injection solutions remains constrained by two simultaneous degradation routes: acid-catalyzed hydrolysis of the ethylamino side chain and metal-catalyzed oxidation of the phenothiazine nucleus to promethazine sulfoxide. The injection is therefore compounded at 25 mg/mL or 50 mg/mL in Water for Injection, adjusted to pH 4.0–5.5 with 1 N hydrochloric acid or 1 N sodium hydroxide, and protected with disodium edetate at 0.10% w/v to chelate trace iron and copper. Dissolved oxygen is reduced by nitrogen sparging for 60 min through a 0.22 μm sterilizing-grade PVDF filter until dissolved oxygen remains below 0.2 mg/L; headspace oxygen in filled vials is maintained below 1.0% v/v by nitrogen overlay. Tonicity is adjusted with sodium chloride to 280–320 mOsm/kg for parenteral administration; hyperosmotic formulations are avoided in intramuscular injections because of injection-site pain and tissue damage. When multidose vials are required, antimicrobial preservative effectiveness must meet USP <51>; benzyl alcohol is avoided in feline formulations because of reported toxicities in cats, whereas phenol at 0.5% w/v or chlorobutanol at 0.5% w/v may be evaluated for target-species compatibility. The filtered solution is aseptically filled into Type I amber borosilicate glass vials and stoppered with chlorobutyl rubber closures; terminal sterilization at 121 °C for 15 min is employed only when forced degradation data demonstrate total impurity area remains below 0.5% after the cycle. Published data for terminal sterilization of veterinary-specific promethazine HCl formulations is limited; therefore filter compatibility, extractables, and leachables are assessed under ICH Q3D and USP <1663> when aseptic processing is selected as the primary sterilization strategy.

Manufacturing line failure modes include trace metal contamination from stainless steel fittings leading to pink-discolored solution and filter fouling from incompletely dissolved antioxidant. In one root-cause investigation, pH drift to 6.0 during scale-up caused free base precipitation as a white haze. In-process checks include pH, color, bioburden, dissolved oxygen, and filter integrity; pre-filtration bioburden is controlled to ≤10 CFU/100 mL per Ph. Eur. 5.1.1. Release testing includes sterility by USP <71> membrane filtration, bacterial endotoxins by USP <85> with a limit calculated for the labeled dose, and subvisible particulate matter by USP <788> Method 1. Typical small-volume parenteral limits are not more than 25 particles per container at ≥10 μm and not more than 3 particles per container at ≥25 μm. Photostability testing per ICH Q1B is included because phenothiazine injections darken under visible and UVA light; amber glass containers are required.

At production scale for companion animal capsule strengths of 10 mg through 50 mg, content uniformity failures typically originate from electrostatic charging of promethazine hydrochloride during low-humidity filling. To mitigate this, the API is pre-screened through a 30-mesh stainless screen and combined with microcrystalline cellulose and lactose monohydrate using two-stage geometric dilution in a bin blender; the final fill weight for a 25 mg capsule is generally 120–180 mg in size 3 or size 4 HPMC or gelatin hard capsules. Magnesium stearate is limited to 0.5% w/w; lot records from encapsulator runs have shown that lubricant blending beyond 20 min prolongs disintegration of the powder plug due to hydrophobic film formation. Relative humidity in the filling suite is maintained at 40–50% RH to reduce static while avoiding powder adhesion to dosator pins or tamping pins. Content uniformity is confirmed against USP <905> with an acceptance value of L1 ≤15.0 for the first 10 units and L1 ≤25.0 for the full set. Dissolution testing uses USP <711> Apparatus 1 at 100 rpm in 900 mL of 0.1 N HCl, with not less than 75% of label claim released at 30 min. Empty capsule shell selection is confirmed for water content and brittleness; HPMC shells with a water content below 5.0% w/w reduce the risk of brittleness during high-speed filling at 60,000–100,000 capsules/h. Published data for promethazine hydrochloride dissolution in this specific HPMC configuration is limited; therefore the dissolution specification should be justified by target-species bioavailability or dissolution profile comparison under USP <711>.

At high-speed filling, environmental oxygen does not immediately affect dry powder; however, warehouse storage in non-barrier bulk containers above 30 °C and 65% RH produces pinkish discoloration within 12 weeks. Bulk capsules are therefore packed in HDPE bottles with desiccant and induction-sealed liners; bulk storage before final packaging should not exceed 30 days at 25 °C / 60% RH unless in-process stability data support longer holding times. Cleaning validation for capsule filling equipment follows FDA 21 CFR 211.67; cross-contamination of phenothiazines into unrelated veterinary product lines must be controlled by swab and rinse limits based on health-based exposure data.

Oral Powder and Granule Dosing Systems for Non-Food Companion Animals

Granulation of promethazine hydrochloride in a top-spray fluid bed is performed to improve flow and reduce dust exposure in veterinary compounding suites. A typical batch of 25 mg/g granules is wet-granulated with povidone K30 at 5.0% w/w solids in purified water, using an inlet air temperature of 55–65 °C and a product temperature held at 30–35 °C; spray rate is adjusted to maintain a final loss on drying of 1.5–2.5% w/w by USP <921>. Sieve analysis of the dried granulation is controlled so that ≥90% of the mass falls between 150 μm and 850 μm; undersized fines are recycled into the next granulation after milling, and oversized material is passed through a 1.0 mm cone mill at 1,500 rpm. The free-flowing granule is filled into single-dose sachets or bulk HDPE containers under ≤30% RH; desiccant is not added when the sachet material is a low-moisture barrier laminate, but a desiccant canister is required for bulk HDPE containers stored in tropical zones. Promethazine hydrochloride has a bitter taste; palatability in cats and dogs therefore requires a species-specific masking system, but published stability data for palatant-coated promethazine granules is limited, so each formulation candidate should be evaluated in target-species acceptability studies. In the EU, promethazine is not included in Table 1 of Regulation (EU) No 37/2010; therefore this powder and granule presentation is confined to non-food animals unless a national residue clearance exists. In the United States, extralabel use in food-producing species is prohibited where no safe tissue residue method or tolerance is available under FDA 21 CFR Part 530.

For direct powder presentation, promethazine hydrochloride is triturated with anhydrous lactose or dicalcium phosphate carrier; batch homogeneity is checked by thief sampling with a target mean content at top, middle, and bottom of ±5.0% of label claim. Blend segregation potential is evaluated by the Hausner ratio; a value below 1.25 is preferred for transport and sachet filling according to USP <1174>. In granulated systems, residual moisture above 2.5% w/w after drying has been associated with granule agglomeration and poor discharge from sachet filling tubes, while over-dried material below 1.0% w/w can fracture and generate fines during transfer.

When Premix Carriers Are Requested for Non-Food Equine or Canine Unit Dosing

Promethazine hydrochloride premixes are not approved medicated feed articles in the European Union or the United States for food-producing species; their preparation is limited to extemporaneous compounding for non-food animals. The dominant stability challenge in a premix carrier is the oxidation of the phenothiazine nucleus during extended storage; the carrier therefore must have low moisture and low peroxide content. Anhydrous dibasic calcium phosphate or pregelatinized starch with a measured loss on drying below 1.0% w/w is preferred over hygroscopic sugars and polyols, which can dissolve the API and accelerate sulfoxide formation at contact points. The API is first pre-blended with 10% w/w of carrier by geometric dilution, then transferred to a tumble blender and mixed for 20 min at 10 rpm; final homogeneity is verified by stratified sampling across top, middle, and bottom discharge ports with individual samples within ±5.0% of the calculated label claim. A 2.0% v/v maximum headspace oxygen limit is applied in heat-sealed foil laminate pouches containing an oxygen absorber; the pouch water vapor transmission rate should not exceed 0.1 g/m²/day at 38 °C / 90% RH. Light protection is mandatory because promethazine sulfoxide formation increases under UVA and visible light. Storage is controlled at 25 °C protected from light; short-term excursions above 40 °C increase total impurities and are not acknowledged as repeat storage conditions.

The premix carrier must be free of peroxide residues from modified starches and of strong oxidizing agents; trace hydrogen peroxide can initiate sulfoxide formation even in a sealed pack. Incompatibility with alkaline carriers is also documented because free base precipitation at elevated pH reduces uniformity and may produce a visible haze when the premix is reconstituted. Premix production lines using gravity-fed fillers require frequent cleaning to avoid cross-contamination; validation follows FDA 21 CFR 211.67 and should include swab limits for promethazine hydrochloride in non-dedicated equipment.

Measured at 25 °C in purified water, promethazine hydrochloride behaves as a freely soluble cationic salt; solubility declines as pH approaches the free base pKa near 9.1. Oral solutions for companion animals are therefore buffered to pH 4.5–5.5 with a 10 mM citrate buffer to maintain the ionized, water-soluble form while limiting acid-catalyzed degradation of the ethylamino side chain. A typical 5 mg/mL solution is compounded by dissolving the API in purified water, adding sodium benzoate at 0.10% w/v and potassium sorbate at 0.10% w/v as preservatives, and sparging with nitrogen to reduce dissolved oxygen before filling. Sweeteners and viscosity modifiers are selected for species-specific acceptability; no single sweetener system has demonstrated universal palatability across feline and canine patients, so formulation development must include target-species acceptance testing. The solution is clarified through a 5 μm depth filter followed by a 0.45 μm membrane filter and filled into amber polyethylene terephthalate bottles with child-resistant closures; the amber container light transmission below 10% across the 320–450 nm range is confirmed by USP <671>. Antimicrobial effectiveness testing follows USP <51>, with acceptance criteria for bacteria at 14 days and fungi at 28 days. Photostability is evaluated under ICH Q1B Option 2 using 1.2 million lux·h visible light and 200 W·h/m² UVA; unacceptable color shifts or assay loss greater than 2.0% indicate insufficient light protection.

In-process pH monitoring is critical; pH drift greater than 0.5 units during six-month storage at 40±2 °C / 75±5% RH indicates inadequate buffer capacity, carbon dioxide ingress, or degradation-related ionic shifts. Oral solution batches are not terminally sterilized; therefore raw water quality, preservative capacity, and package integrity are the primary microbial controls. Published stability data for sweetened promethazine oral solutions in veterinary-specific formulations is limited; bracketing at the lower and upper pH limits is required to justify the selected buffer system.